Driving Industry Adoption
Facebook Twitter LinkedIn

Case Study: How an Entire Industry adopts Digital Enterprise Identity

Combined Session
Wednesday, September 15, 2021 15:30—15:50

Back in November 2013 the U.S. congress enacted the Drug Supply Chain Security Act (DSCSA). Part of the regulation is that actors within the U.S. pharmaceutical industry must verify the U.S. state license, which is issued by the U.S. Drug Enforcement Administration (DEA), status (and thus the authenticity) of every trading partner within their supply chain. And this does not stop just by direct trading partners a pharmaceutical supply chain actor might have, the regulation states, that also indirect trading partner’s U.S. state license status must be proofed.

The overall objective of these new upcoming regulations is to better protect the U.S. pharmaceutical supply chain of illegitimate products, thus increasing U.S. consumer’s security. The authorities set the deadline to the industry to be compliant with the law by November 2023. The DSCSA demands the industry to implement a full interoperable electronic system to be able to verify also indirect trading partner relationships in less then 24h.

Today in 2021, U.S. pharmaceutical supply chain actors have no mechanism to validate their trading partners licenses. There are 70.000 interacting trading partners involved in the U.S. pharmaceutical industry. Saying, a solution to be compliant with the regulations by 2023 is highly demanded.

Dr. Carsten Stöcker
Dr. Carsten Stöcker
Dr. Carsten Stöcker is co-founder and CEO of Spherity. Spherity is building decentralized digital identity management solutions to power the fourth industrial revolution.Carsten...


On-Demand Access
Re-live EIC 2021
Watch more than 250 sessions on-demand
Download all available presentations
Subscribe for updates
Please provide your email address